Iktos

Company profile

About Iktos

Iktos is a pioneering AI and robotics company transforming drug discovery through fully integrated automation. Founded in 2016 and headquartered in Paris, France, Iktos has developed a comprehensive platform that combines generative AI, retrosynthesis planning, and robotic automation to accelerate the drug discovery process. The company's flagship product, Makya, is a generative AI SaaS platform designed by chemists for chemists that creates diverse, novel, and synthetically accessible molecules optimized for drug development. Spaya, their AI-driven retrosynthesis platform, rapidly identifies feasible synthetic routes by converting target compounds into commercially available starting materials in seconds. Iktos Robotics completes the ecosystem by managing the entire synthetic process through automated workflows, from ordering raw materials to executing chemical synthesis, purification, analysis, and biological testing. The platform enables a fully digitized, AI-driven Design-Make-Test-Analyze (DMTA) cycle that significantly reduces drug discovery timelines to under 24 months. Iktos serves pharmaceutical companies, biotech firms, and academic institutions, having completed over 60 collaborations since inception. The company maintains an in-house pipeline targeting areas including inflammation, auto-immune diseases, obesity, metabolism, and immuno-oncology. Iktos has been recognized with a prestigious European Innovation Council (EIC) Accelerator grant for its groundbreaking work integrating generative AI, robotics, and high-precision biological screening.

Company description · Iktos official website